Abiopharma

🔍 Sachs David C. (Executive)

Company: ImmunityBio, Inc. (IBRX)

Report Date: 2025-12-31

Detailed Transactions and Holdings:

• Acquired 30,397 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 256,017.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 15,435 shares of Common Stock at $1.98 per share (Direct)
  Date: 2025-12-31 | Code: F | equity_swap_involved: 0 | shares_owned_after: 240,582.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 30,397 shares of Restricted Stock Units (Derivative)
  Date: 2025-12-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 45,602.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
• F2: On December 31, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 30, 2025 was the settlement price used to calculate the shares withheld.
• F3: 17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.
• REMARKS: Exhibit 24 - Power of Attorney